Proxima
Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes.
About Proxima
Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes. It focuses on creating proximity-modulating therapeutics that direct protein interactions for potential use in conditions such as autoimmune disorders and cancer, expanding the range of targets that traditional drugs cannot easily reach. Proxima Bio combines structural biology, data generation, and machine learning to identify actionable protein-protein interfaces and support the discovery of new therapeutic modalities. The company works with pharmaceutical partners to apply its platform in research collaborations and advance drug discovery pipelines. Proxima Bio’s platform integrates multiple technologies to support the design and discovery of novel proximity-based treatment approaches.
Company Facts
- Headquarters
- New York
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00011_00050
- Funding Stage
- seed
- Total Funding
- $86,264,999
- Last Funding Type
- seed
- Last Funding Date
- 2026-01-13
- Website
- proximabio.com
Industries & Categories
Alternative Medicine, Artificial Intelligence (AI), Biotechnology, Clinical Trials, Life Science, Machine Learning
Social Links
Canonical: https://fsome.com/organization/proxima-38288 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.